HER2 Positive Breast Carcinoma

Known as: HER2 Overexpressing Subtype of Breast Carcinoma, HER2 Overexpressing Breast Carcinoma, HER2 Positive Breast Cancer 
A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally. We have characterized the role of… (More)
Is this relevant?
2013
2013
About 20% of breast cancers are characterized by amplification and overexpression of the HER2 oncogene. Although significant… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Background: Brain metastases are frequently encountered in Her2 positive advanced breast cancer. It is still not clear, if… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4F (eIF4F… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Efflux is an important resistance mechanism in Staphylococcus aureus, but its frequency in patients with bacteremia is unknown… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Breast cancer resistance protein (BCRP) is a newly identified ATP-binding cassette transporter, shown to confer multidrug… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Trastuzumab, which is a large monoclonal antibody that is efficacious in the treatment of patients with HER-2/neu… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Women with HER-2 overexpressing metastatic breast carcinoma benefit from trastuzumab-based therapy, but trastuzumab… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
PURPOSE To determine the toxicity, pharmacokinetics, response rate, and response duration of intravenous (i.v.) administration of… (More)
Is this relevant?